首页> 外国专利> ARF-BP1 AS MEDIATOR OF P53-DEPENDENT AND INDEPENDENT TUMOR SUPPRESSION AND USES THEREOF

ARF-BP1 AS MEDIATOR OF P53-DEPENDENT AND INDEPENDENT TUMOR SUPPRESSION AND USES THEREOF

机译:ARF-BP1作为P53依赖性和独立性肿瘤抑制因子的介体及其用途

摘要

The present invention relates to the mechanism of ARF-mediated cell growth suppression. ARF-BP1 is identified as a novel ubiquitin ligase, and a major component of ARF-containing nuclear complexes in human cells. The present invention discloses a novel mechanism of ARF-mediated p53 activation and that ARF-BP1 is a critical mediator of both p53-independent and p53-dependent tumor suppression functions of ARF. Inactivation of ARF-BP1 in normal cells stabilizes p53 and induces p53-dependent apoptosis. Inactivation of ARF-BP1, but not Mdm2, in p53-wildtype cells promotes cell growth inhibition in a manner reminiscent of ARF induction. ARF-BP1 directly binds and ubiquitinates p53 and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization in Mdm2-null cells. ARF-BP1 is advantageous over Mdm2 as a target for suppressing tumor cell growth regardless of p53 status.
机译:本发明涉及ARF介导的细胞生长抑制的机制。 ARF-BP1被鉴定为一种新型的泛素连接酶,是人细胞中含ARF的核复合物的主要成分。本发明公开了ARF介导的p53活化的新机制,并且ARF-BP1是ARF的p53非依赖性和p53依赖性肿瘤抑制功能的关键介质。正常细胞中ARF-BP1的失活可稳定p53并诱导p53依赖性细胞凋亡。在p53野生型细胞中,ARF-BP1的失活而不是Mdm2的失活以类似于ARF诱导的方式促进细胞生长抑制。 ARF-BP1直接结合并泛素化p53,内源性ARF-BP1的失活对于Mdm2-null细胞中ARF介导的p53稳定至关重要。不论p53状态如何,ARF-BP1都优于Mdm2作为抑制肿瘤细胞生长的靶标。

著录项

  • 公开/公告号KR20070091602A

    专利类型

  • 公开/公告日2007-09-11

    原文格式PDF

  • 申请/专利号KR20077008508

  • 发明设计人 GU WEI;

    申请日2007-04-13

  • 分类号C07K14/47;C12N9/64;C12P21/06;G01N33/574;

  • 国家 KR

  • 入库时间 2022-08-21 20:33:34

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号